Back to Journals » Hepatic Medicine: Evidence and Research » Volume 10

Biomarkers for primary biliary cholangitis: current perspectives

Authors Kouroumalis E, Samonakis D, Voumvouraki A

Received 9 March 2018

Accepted for publication 24 April 2018

Published 18 June 2018 Volume 2018:10 Pages 43—53


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Gerry Lake-Bakaar

Elias Kouroumalis,1 Demetrius Samonakis,2 Argyro Voumvouraki3

1Department of Gastroenterology, University Hospital and Medical School, University of Crete, Heraklion, Crete, Greece; 2Department of Gastroenterology, University Hospital of Heraklion, Crete, Greece; 3Department of Medicine, AHEPA University Hospital, Thessaloniki, Greece

Abstract: Primary biliary cholangitis (PBC) is a chronic progressive cholestatic disease characterized by destruction of small- and medium-sized intrahepatic bile ducts. It is no longer a rare disease, since many new asymptomatic cases are incidentally identified. Liver biopsy is diagnostically critical but not always feasible or practical to be performed. Many potential, noninvasive, markers have been proposed to replace liver biopsy and further provide the assessment of disease severity and ultimate prognosis. In this review, we evaluated serum biomarkers proposed for diagnosis, extent of fibrosis, disease prognosis and attempts for early prediction of treatment response. Older biochemical and immunological markers are presented along with recent reports including the role of microRNAs and promising results based on proteomics and metabolomics.

Keywords: primary biliary cholangitis, autoantibodies, microRNAs, proteomics, treatment response

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]